Abstract Details

Title Harry Lee Parker and Paroxysmal Dysarthria and Ataxia

Topic History of Neurology

Presentation(s) P05 - (-)

Poster/Presentation
Number 254

Objective

Background BACKGROUND: Paroxysmal motor and sensory phenomena are well-described complications of MS. There is, however, disagreement about who first described paroxysmal dysarthria and ataxia.

Design/Methods DESIGN/METHODS: Evaluation of original publications describing paroxysmal dysarthria and ataxia, bibliographic information, writings, and unpublished letters from the Mayo Clinic Historical Unit.

Results RESULTS: In 1940, Gustav Storring described an MS patient with paroxysmal symptoms that included dizziness and trouble speaking, but also unilateral extremity weakness. In 1946, Parker published a series of 11 patients with paroxysmal dysarthria and ataxia. Six of these patients had MS, and he recognized this phenomenon as a manifestation of the disease. The term "paroxysmal dysarthria and ataxia" was first used in 1959 by Frederick Andermann and colleagues. Since that time, paroxysmal dysarthria and ataxia has become a well-recognized phenomenon in MS. More recent reports have suggested that the responsible lesion is located in the midbrain, near or involving the red nucleus.

Conclusions CONCLUSIONS: Parker was the first to accurately describe paroxysmal dysarthria and ataxia in multiple sclerosis patients.

Authors/Disclosures
James P. Klaas, MD, FAAN PRESENTER	An immediate family member of Dr. Klaas has received publishing royalties from a publication relating to health care.
David B. Burkholder, MD, FAAN (Mayo Clinic)	The institution of Dr. Burkholder has received research support from Longboard pharmaceuticals.
Wolfgang Singer, MD, FAAN (Mayo Clinic)	Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. The institution of Dr. Singer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Singer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
Christopher J. Boes, MD, FAAN (Mayo Clinic)	Dr. Boes has a non-compensated relationship as a Review Committee for Neurology member with ACGME that is relevant to AAN interests or activities.
Kennedy Lees, MD (Western Infirmary)	No disclosure on file

��ɫ��

��ɫ��